Prolotherapy in the treatment of chronic migraine — Case report




Prolotherapy, Chronic migraine, Dextrose, Migraine


Chronic migraine is a socioeconomic and individual burden since it is the largest cause of disability in people under 50 years of age. Although there are several prophylactic drug alternatives, some patients are vulnerable to refractoriness with significant damage to their quality of life. Prolotherapy, a subcutaneous injection of dextrose in peripheral nerves, advocates as a promising tool in the management of this pathology.
Case report
A patient with refractory chronic migraine to drug therapy who was submitted to neurofascial prolotherapy. Weekly administration of a 2 ml solution of 1% ropivacaine and 10% glucose in the head peripheral nerves for 6 weeks. Reduced disability and frequency of migraine attacks for a period of 8 weeks after interventions.
Prolotherapy proved itself to be a notable technique for reducing the number of days in a month that a patient with refractory chronic migraine to standardized therapy has had headaches. However, placebo group studies are needed to determine the efficacy of the procedure.


Download data is not yet available.


Steiner TJ, Stovner LJ, Vos T, Jensen R and Katsarava Z. The Journal of Headache and Pain 2018; 19(1):10 Doi:10.1186/s10194-018-0846-2 DOI:

Malta DC, Bernal RTI, Lima MG, Araújo SSC, Silva MMA, Freitas MIF and Barros MBA. Noncommunicable diseases and the use of health services: analysis of the National Health Survey in Brazil. Revista de Saúde Pública 2017; 51(suppl 1): Doi:10.1590/s1518-8787.2017051000090 DOI:

Malta DC, Stopa SR, Szwarcwald CL, Gomes NL, Silva Júnior JB and Reis AAC. A vigilância e o monitoramento das principais doenças crônicas não transmissíveis no Brasil - Pesquisa Nacional de Saúde, 2013. Revista Brasileira de Epidemiologia 2015; 18(suppl 2): 3-16 Doi:10.1590/1980-5497201500060002 DOI:

Peres MFP, Oliveira AB, Sarmento EM, Rocha-Filho PS, Peixoto PM, Kowacs F, . . . Bensenor IJ. Public policies in headache disorders: needs and possibilities. Arquivos de Neuro-Psiquiatria 2020; 78(1): 50-52 Doi:10.1590/0004-282x20190144 DOI:

Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmento EM, Katsarava Z and Steiner TJ. Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. The Journal of Headache and Pain 2019; 20(1):85 Doi:10.1186/s10194-019-1036-6 DOI:

Hovaguimian A and Roth J. Management of chronic migraine. Bmj 2022; e067670 Doi:10.1136/bmj-2021-067670 DOI:

Lyftogt J What is Lyftogt Perineural Injection Treatment? Lyftogtmed; 2016 [update cited 2023 June 12]. Available from:

Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA and Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine 2002; 8(2): 136-142 Doi:10.1038/nm0202-136 DOI:

Moskowitz MA, Nozaki K and Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. The Journal of Neuroscience 1993; 13(3): 1167-1177 Doi:10.1523/jneurosci.13-03-01167.1993 DOI:

Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Koçak E, Sen ZD and Dalkara T. Spreading Depression Triggers Headache by Activating Neuronal Panx1 Channels. Science 2013; 339(6123): 1092-1095 Doi:10.1126/science.1231897 DOI:

Goadsby PJ, Edvinsson L and Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Annals of Neurology 1988; 23(2): 193-196 Doi:10.1002/ana.410230214 DOI:

Sarchielli P, Alberti A, Floridi A and Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001; 57(1): 132-134 Doi:10.1212/wnl.57.1.132 DOI:

Geppetti P, Nassini R, Materazzi S and Benemei S. The concept of neurogenic inflammation. BJU International 2008; 101(s3): 2-6 Doi:10.1111/j.1464-410X.2008.07493.x DOI:

Simone DA, Ngeow JYF, Putterman GJ and LaMotte RH. Hyperalgesia to heat after intradermal injection of capsaicin. Brain Research 1987; 418(1): 201-203 Doi:10.1016/0006-8993(87)90982-6 DOI:

Jancsó N, Jancsó-GáBor A and Szolcsányi J. Direct Evidence for Neurogenic Inflammation and Its Prevention by Denervation and by Pretreatment with Capsaicin. British Journal of Pharmacology and Chemotherapy 1967; 31(1): 138-151 Doi:10.1111/j.1476-5381.1967.tb01984.x DOI:

Weglein AD. Neural Prolotherapy. Journal of Prolotherapy 2001; 3(2): 639-643

Eileen Conaway BB Neural Prolotherapy for Neuralgia: Journal of Prolotherapy; 2014 [update cited 2023 June 12]. Available from:

Anand P and Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107(4): 490-502 Doi:10.1093/bja/aer260 DOI:

Lim HJ, Hasan MS, Chinna K. Faster onset time of supraclavicular brachial plexus block using local anesthetic diluted with dextrose. Rev Bras Anestesiol. 2016; 66(4):341-345 Doi: 10.1016/j.bjan.2016.04.006 DOI:




How to Cite

Bernardo Souto Ítallo, Santos de Lima FF, Arapiraca Ferreira V, Batista Lopes CE, Lacerda Sousa LG, Egypto Pereira V, Severo Bem Junior L. Prolotherapy in the treatment of chronic migraine — Case report . Headache Med [Internet]. 2023 Sep. 18 [cited 2024 Mar. 2];14(2):116-23. Available from:



Case Report

Most read articles by the same author(s)